Cargando…

pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies

The objective of the current study was to achieve a sustained release profile of capecitabine (CAP), an anticancer agent frequently administered in conventional dosage form due to its short plasma half-life. A drug-loaded smart pH responsive chitosan/fenugreek-g-poly (MAA) hydrogel was synthesized b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Umaira, Sarfraz, Rai Muhammad, Mahmood, Asif, Akbar, Shehla, E. Altyar, Ahmed, Khinkar, Roaa M., Gad, Heba A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778381/
https://www.ncbi.nlm.nih.gov/pubmed/36547299
http://dx.doi.org/10.3390/gels8120775
_version_ 1784856345547112448
author Rehman, Umaira
Sarfraz, Rai Muhammad
Mahmood, Asif
Akbar, Shehla
E. Altyar, Ahmed
Khinkar, Roaa M.
Gad, Heba A.
author_facet Rehman, Umaira
Sarfraz, Rai Muhammad
Mahmood, Asif
Akbar, Shehla
E. Altyar, Ahmed
Khinkar, Roaa M.
Gad, Heba A.
author_sort Rehman, Umaira
collection PubMed
description The objective of the current study was to achieve a sustained release profile of capecitabine (CAP), an anticancer agent frequently administered in conventional dosage form due to its short plasma half-life. A drug-loaded smart pH responsive chitosan/fenugreek-g-poly (MAA) hydrogel was synthesized by an aqueous free radical polymerization technique. The developed network was evaluated for capecitabine loading %, swelling response, morphology, structural and compositional characteristics, and drug release behavior. Significantly higher swelling and in vitro drug release rate were exhibited by formulations at pH 7.4 than at pH 1.2, demonstrating the pH responsive character of hydrogels. Swelling percentage and CAP loading ranged within 74.45–83.54% and 50.13–72.43%, respectively. Maximum release, up to 93%, was demonstrated over 30 h, evidencing the controlled release pattern of CAP from hydrogels. The optimized formulation was further screened for acute oral toxicity studies. No signs of oral, dermal, or ocular toxicities were noticed, confirming safety evidence of the network. Furthermore, pharmacokinetic analysis demonstrated the sustained release response of CAP from hydrogels as confirmed by a significant increase in plasma half-life (t(1/2)) (13 h) and AUC (42.88 µg h/mL) of CAP. Based on these findings, fabricated hydrogels are strongly recommended as a biocompatible carrier for colorectal delivery of active agents.
format Online
Article
Text
id pubmed-9778381
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97783812022-12-23 pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies Rehman, Umaira Sarfraz, Rai Muhammad Mahmood, Asif Akbar, Shehla E. Altyar, Ahmed Khinkar, Roaa M. Gad, Heba A. Gels Article The objective of the current study was to achieve a sustained release profile of capecitabine (CAP), an anticancer agent frequently administered in conventional dosage form due to its short plasma half-life. A drug-loaded smart pH responsive chitosan/fenugreek-g-poly (MAA) hydrogel was synthesized by an aqueous free radical polymerization technique. The developed network was evaluated for capecitabine loading %, swelling response, morphology, structural and compositional characteristics, and drug release behavior. Significantly higher swelling and in vitro drug release rate were exhibited by formulations at pH 7.4 than at pH 1.2, demonstrating the pH responsive character of hydrogels. Swelling percentage and CAP loading ranged within 74.45–83.54% and 50.13–72.43%, respectively. Maximum release, up to 93%, was demonstrated over 30 h, evidencing the controlled release pattern of CAP from hydrogels. The optimized formulation was further screened for acute oral toxicity studies. No signs of oral, dermal, or ocular toxicities were noticed, confirming safety evidence of the network. Furthermore, pharmacokinetic analysis demonstrated the sustained release response of CAP from hydrogels as confirmed by a significant increase in plasma half-life (t(1/2)) (13 h) and AUC (42.88 µg h/mL) of CAP. Based on these findings, fabricated hydrogels are strongly recommended as a biocompatible carrier for colorectal delivery of active agents. MDPI 2022-11-28 /pmc/articles/PMC9778381/ /pubmed/36547299 http://dx.doi.org/10.3390/gels8120775 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rehman, Umaira
Sarfraz, Rai Muhammad
Mahmood, Asif
Akbar, Shehla
E. Altyar, Ahmed
Khinkar, Roaa M.
Gad, Heba A.
pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title_full pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title_fullStr pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title_full_unstemmed pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title_short pH Responsive Hydrogels for the Delivery of Capecitabine: Development, Optimization and Pharmacokinetic Studies
title_sort ph responsive hydrogels for the delivery of capecitabine: development, optimization and pharmacokinetic studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778381/
https://www.ncbi.nlm.nih.gov/pubmed/36547299
http://dx.doi.org/10.3390/gels8120775
work_keys_str_mv AT rehmanumaira phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT sarfrazraimuhammad phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT mahmoodasif phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT akbarshehla phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT ealtyarahmed phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT khinkarroaam phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies
AT gadhebaa phresponsivehydrogelsforthedeliveryofcapecitabinedevelopmentoptimizationandpharmacokineticstudies